What is Cerebrolysin used for? What the trials actually show

What is Cerebrolysin?

Cerebrolysin is a mixture of small peptides and amino acids taken from pig brain, given as a series of intravenous infusions. It is used after strokes and brain injuries and for dementia in over 45 countries, mainly Russia, Eastern Europe and Asia. Its exact mechanism of action is uncertain.

Most peptides people read about are one defined molecule: a chain of a known sequence, made in a laboratory. Cerebrolysin is different. The Cochrane review of its use in stroke describes it as a mixture of low-molecular-weight peptides and amino acids derived from porcine brain [1], that is, pig brain. A 2021 review groups it with a similar Russian product, Cortexin, as neuropeptide preparations of biologically active peptides isolated from pig brains [5].

That makes it a product rather than a single compound, closer to an extract than to a synthetic peptide like semaglutide or BPC-157. It is given as a series of daily intravenous infusions [4], and the 2021 review notes that needing frequent infusions is itself a treatment burden [5].

Where is it used? According to the same review, Cerebrolysin is used to treat traumatic brain injury, stroke and dementia in over 45 countries, including Russia and China [5]. The Cochrane stroke review describes it as widely used for acute ischaemic stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries [1]. How it works is not settled: reviewers describe its exact mechanism of action as uncertain [5], and its claimed brain-protective properties as potential ones [1].

Does Cerebrolysin work for stroke?

Not convincingly. Its largest trial, 1,070 stroke patients in Asia, found no difference on its main measure. The 2023 Cochrane review of seven trials found it probably makes little or no difference to deaths. One smaller, manufacturer-funded rehabilitation trial reported better arm function and called its own result exploratory.

Stroke is Cerebrolysin's main use, so it is where the evidence matters most. Three pieces of it are worth knowing.

• The largest trial was neutral. A double-blind trial in Asia enrolled 1,070 patients [2], randomized within 12 hours of an ischaemic stroke [2]. Its confirmatory endpoint showed no significant difference between Cerebrolysin and placebo [2]. A post hoc analysis, one done after the results were in, found a favourable trend in the most severely affected patients, which the authors said should be confirmed by a further trial [2].
• The independent review finds no effect on death. The 2023 Cochrane review pooled seven randomised trials with 1,773 participants [1]. It concluded that Cerebrolysin or the similar product Cortexin probably make little to no difference in all-cause death [1]. None of the included studies reported the outcome that matters most after a stroke, death or dependence at the end of follow-up [1], and the manufacturer supported three of the multicentre studies [1].
• One rehabilitation trial was positive. CARS enrolled 208 patients [3] who also did a standardised 21-day rehabilitation programme [3]. On its primary endpoint, an arm function test at day 90 [3], it reported a large superiority of Cerebrolysin over placebo [3]. The trial was funded by the manufacturer, EVER Neuro Pharma [3], and its authors describe it as exploratory, with a relatively small sample, needing confirmation in a large trial [3].

Put together, for the randomised evidence covered here: the biggest trial and the independent review do not show a benefit on their main questions, and the positive results come from smaller or post hoc analyses that their own authors say need confirming.

Does Cerebrolysin work for dementia?

Reviews find small improvements in thinking scores, but on weak evidence. A Cochrane review of six vascular dementia trials found benefits from very low-quality studies at high risk of bias, possibly too small to matter. A broader review rated the certainty low to very low.

Cerebrolysin is also promoted for memory problems, especially vascular dementia, the kind caused by damage to the brain's blood supply. The best summary is the 2019 Cochrane review, which found six randomised trials with a total of 597 participants [4].

On paper the result was positive: courses of intravenous Cerebrolysin improved cognition and general function [4]. But the authors immediately add that the data are not definitive [4]. The trials were mixed and at high risk of bias, and if there are benefits, they may be too small to be clinically meaningful [4]. Where funding was reported, all the studies were supported by the pharmaceutical industry [4]. Their bottom line is blunt: Cerebrolysin continues to be used and promoted for vascular dementia, but the supporting evidence base is weak [4].

A 2021 review of animal-derived nootropics, Cerebrolysin and two similar products, reached a similar place. Across its studies, risk of bias was moderate to high and the certainty of evidence low to very low [5], and the effects it found were modest and probably less than would be considered clinically relevant [5].

For Alzheimer's disease, a 2015 meta-analysis of 6 placebo-controlled trials [6] concluded that Cerebrolysin has an overall beneficial effect and a favourable benefit-risk ratio in mild to moderate disease [6]. It is the most positive reading in this list, and it sits beside two independent reviews that call the evidence weak.

Why the Cerebrolysin evidence is hard to judge

Because the trials are small, varied and often at risk of bias. Reviewers found missing outcome data in four of seven stroke trials, doses and treatment lengths that differ from study to study, follow-up from 15 days to three years, and manufacturer support behind many of the studies.

A reader who searches for Cerebrolysin will find confident claims in both directions. The reason is the shape of the evidence, and it is worth seeing why each review lands where it does.

First, the trials do not look alike. In vascular dementia, the included studies tested varying doses and durations of treatment [4], with follow-up ranging from 15 days to three years [4]. The 2021 review of animal-derived nootropics notes that, although these drugs are used internationally, reports on their efficacy have been conflicting [5]. Pooling such different studies into one number is possible, but the number is only as solid as the studies under it.

Second, quality problems recur. In the stroke review, incomplete outcome data were judged a low risk of bias in three studies and a high risk in the remaining four [1], and two studies were judged at high risk of other bias [1].

Third, much of the research is funded by the maker. The manufacturer supported three of the multicentre stroke studies [1], funded the positive rehabilitation trial [3], and in vascular dementia every study that reported its funding was supported by industry [4]. Industry funding does not make a result wrong. It is a reason to give extra weight to independent reviews. The vascular dementia review ends by asking for adequately powered, methodologically robust trials [4], and the stroke review's conclusions are that Cerebrolysin probably has no benefit on death and may raise non-fatal serious adverse events [1].

Is Cerebrolysin safe?

In trials, the overall rate of side effects was similar to placebo. But the 2023 Cochrane stroke review found moderate-certainty evidence of a rise in non-fatal serious adverse events with Cerebrolysin, a risk ratio of 2.39 across three trials. Reviews in dementia found no difference.

Overall adverse event rates look similar to placebo. In stroke, Cerebrolysin or similar peptide mixtures may make little to no difference in the total number of people with adverse events [1]. In a review across dementia trials there was no difference in serious adverse events [5], and the vascular dementia review reported no suggestion of adverse effects [4].

The one signal that stands out comes from the stroke review. It found an increase in the number of people with non-fatal serious adverse events: a risk ratio of 2.39 across 3 trials and 1,335 participants, with moderate-certainty evidence [1]. Its authors list this among their main conclusions: a potential increase in non-fatal serious adverse events with Cerebrolysin use [1].

All of these trials used the licensed product, given by infusion under medical supervision. None of them says anything about material sold online under the same name.